Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amyris Inc (AMRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 384,161
  • Shares Outstanding, K 76,526
  • Annual Sales, $ 80,420 K
  • Annual Income, $ -211,350 K
  • 60-Month Beta 0.29
  • Price/Sales 3.98
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.33
  • Number of Estimates 1
  • High Estimate -0.33
  • Low Estimate -0.33
  • Prior Year -1.79
  • Growth Rate Est. (year over year) +81.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.87 +168.45%
on 03/26/19
5.13 -2.14%
on 04/18/19
+1.21 (+31.76%)
since 03/18/19
3-Month
1.87 +168.45%
on 03/26/19
6.06 -17.16%
on 02/08/19
+1.43 (+39.83%)
since 01/18/19
52-Week
1.87 +168.45%
on 03/26/19
9.28 -45.93%
on 10/09/18
-1.40 (-21.81%)
since 04/18/18

Most Recent Stories

More News
AMRS CLASS ACTION NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Amyris, Inc. - AMRS

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Amyris, Inc. (NASDAQ: AMRS) from March 15, 2018 and March...

AMRS : 5.02 (+20.10%)
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Amyris, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amyris, Inc. ("Amyris" or "the Company") (NASDAQ:...

AMRS : 5.02 (+20.10%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Amyris, comScore, Mueller Water, and Orion Group and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Amyris, Inc., comScore, Inc., Mueller Water Products, Inc., and Orion Group Holdings,...

AMRS : 5.02 (+20.10%)
SCOR : 12.92 (-2.27%)
MWA : 10.99 (-0.27%)
ORN : 2.71 (unch)
AMYRIS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Northern District of California against Amyris, Inc.

Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a class action lawsuit has been filed against Amyris, Inc. ("Amyris" or the "Company") (NASDAQ: AMRS) in the United States District Court...

AMRS : 5.02 (+20.10%)
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amyris, Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcomingJune 3, 2019deadline to file a lead plaintiff motion in the class action filed on behalf of Amyris, Inc. ("Amyris"...

AMRS : 5.02 (+20.10%)
Amyris Completes Sale of Vitamin E Royalty to DSM

Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced the sale of its...

AMRS : 5.02 (+20.10%)
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amyris, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amyris, Inc. ("Amyris" or "the Company") (NASDAQ: AMRS) for violations of §§10(b)...

AMRS : 5.02 (+20.10%)
Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Amyris, Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against Amyris, Inc. (Nasdaq: AMRS) ("Amyris") on behalf of...

AMRS : 5.02 (+20.10%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amyris, Inc. - AMRS

Pomerantz LLP is investigating claims on behalf of investors of Amyris, Inc. ("Amyris" or the "Company") (NASDAQ: AMRS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com...

AMRS : 5.02 (+20.10%)
Amyris Repays in Cash April 2019 Convertible Note Debt

Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has repaid...

AMRS : 5.02 (+20.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade AMRS with:

Business Summary

Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged...

See More

Key Turning Points

2nd Resistance Point 5.68
1st Resistance Point 5.35
Last Price 5.02
1st Support Level 4.47
2nd Support Level 3.92

See More

52-Week High 9.28
Fibonacci 61.8% 6.45
Fibonacci 50% 5.58
Last Price 5.02
Fibonacci 38.2% 4.70
52-Week Low 1.87

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar